SJG-136

DRUG4 trials

Sponsors

National Cancer Institute (NCI)

Conditions

Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Blastic Phase Chronic Myelogenous LeukemiaPreviously Treated Myelodysplastic SyndromesRecurrent Adult Acute Lymphoblastic Leukemia

Phase 1

SJG-136 in Treating Patients With Advanced Solid Tumors

CompletedNCT00103220

National Cancer Institute (NCI)Unspecified Adult Solid Tumor, Protocol Specific

Start: 2004-11-30Target: 36Updated: 2013-12-11

SJG-136 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery

CompletedNCT00121290

National Cancer Institute (NCI)Unspecified Adult Solid Tumor, Protocol Specific

Start: 2005-02-28Updated: 2014-02-24

SJG-136 in Treating Patients With Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndromes, Blastic Phase Chronic Myelogenous Leukemia, or Chronic Lymphocytic Leukemia

TerminatedNCT00301769

National Cancer Institute (NCI)Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12) +11

Start: 2005-12-31Updated: 2013-09-30

Phase 2

SJG-136 in Treating Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer That Did Not Respond to Previous Treatment With Cisplatin or Carboplatin

TerminatedNCT01200797

National Cancer Institute (NCI)Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer

Start: 2010-07-31End: 2013-02-28Updated: 2015-05-25